141 related articles for article (PubMed ID: 12966421)
1. Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer.
Goffin JR; Straume O; Chappuis PO; Brunet JS; Bégin LR; Hamel N; Wong N; Akslen LA; Foulkes WD
Br J Cancer; 2003 Sep; 89(6):1031-4. PubMed ID: 12966421
[TBL] [Abstract][Full Text] [Related]
2. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
3. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.
Foulkes WD; Brunet JS; Stefansson IM; Straume O; Chappuis PO; Bégin LR; Hamel N; Goffin JR; Wong N; Trudel M; Kapusta L; Porter P; Akslen LA
Cancer Res; 2004 Feb; 64(3):830-5. PubMed ID: 14871808
[TBL] [Abstract][Full Text] [Related]
4. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
5. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
6. Microvessel density and p53 overexpression in young women with breast cancer: a case-control study.
Kalfon B; Fineberg S; Gu Y; Anand K; Dalal A ; Jones J; Sparano JA
Clin Breast Cancer; 2001 Apr; 2(1):67-72. PubMed ID: 11899385
[TBL] [Abstract][Full Text] [Related]
7. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
[TBL] [Abstract][Full Text] [Related]
8. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Lakhani SR; Van De Vijver MJ; Jacquemier J; Anderson TJ; Osin PP; McGuffog L; Easton DF
J Clin Oncol; 2002 May; 20(9):2310-8. PubMed ID: 11981002
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
[TBL] [Abstract][Full Text] [Related]
10. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
J Natl Cancer Inst; 1999 Dec; 91(24):2112-7. PubMed ID: 10601383
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and p53 protein expression in breast cancer: prognostic roles and interrelationships.
Tas F; Yavuz E; Aydiner A; Saip P; Disci R; Iplikci A; Topuz E
Am J Clin Oncol; 2000 Dec; 23(6):546-53. PubMed ID: 11202793
[TBL] [Abstract][Full Text] [Related]
12. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
[TBL] [Abstract][Full Text] [Related]
14. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
[TBL] [Abstract][Full Text] [Related]
15. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.
Chappuis PO; Kapusta L; Bégin LR; Wong N; Brunet JS; Narod SA; Slingerland J; Foulkes WD
J Clin Oncol; 2000 Dec; 18(24):4045-52. PubMed ID: 11118465
[TBL] [Abstract][Full Text] [Related]
16. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
[TBL] [Abstract][Full Text] [Related]
18. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
Chappuis PO; Donato E; Goffin JR; Wong N; Bégin LR; Kapusta LR; Brunet JS; Porter P; Foulkes WD
Ann Oncol; 2005 May; 16(5):735-42. PubMed ID: 15802279
[TBL] [Abstract][Full Text] [Related]
19. Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia.
Budroni M; Cesaraccio R; Coviello V; Sechi O; Pirino D; Cossu A; Tanda F; Pisano M; Palomba G; Palmieri G
BMC Cancer; 2009 Feb; 9():62. PubMed ID: 19232099
[TBL] [Abstract][Full Text] [Related]
20. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]